Sebacia Inc.

Oct 25, 2019

Sebacia Reports New Long-Term Real-World Results Demonstrating 92% Average Improvement in Acne at 24 Months

Oct 24, 2019

Sebacia Announces Oral Presentations Reporting 24-Month EU Real-World Data and 3-Month U.S. Real-World Data of Sebacia Microparticles at ASDS Annual Meeting 2019

Mar 26, 2019

Sebacia to Present 12-Month Durability Data and New in Vivo Imaging Data for Sebacia Microparticles at ASLMS Annual Meeting 2019

Oct 30, 2018

Nanospectra Biosciences Technology Advances Partner Products to US Commercialization

Oct 11, 2018

Sebacia EU Real-World Results Demonstrate an Average 79% Improvement in Acne at 6 Months

Sep 17, 2018

U.S. FDA Clears Sebacia Microparticles for the Treatment of Mild to Moderate Inflammatory Acne

May 07, 2018

Sebacia Announces Favorable Ruling by U.S. Court of Appeals for the Federal Circuit Regarding Patent Interference Proceedings with Sienna Biopharmaceuticals, Inc.

Apr 09, 2018

Sebacia Announces Presentation of Data Demonstrating Sebacia Microparticles as an Effective Contrast Enhancing Agent for Potential Use in Evaluating Dermatologic Conditions